Pharmaxis chief executive Alan Robertson says he has an anxious few weeks ahead as the company waits to find out the US Food and Drug Administration advisory committee recommendations on its Bronchitol drug.
Pharmaxis chief executive Alan Robertson says he has an anxious week ahead until the end of the month when the company will find out the US Food and Drug Administration advisory committee recommendations on whether to accept its Bronchitol drug to treat cystic fibrosis.
The FDA will make a final decision about whether to accept Bronchitol in the US market by mid-March, possibly opening the door to the largest market globally for the biotech.
